‘Smoking Cessation-Epidemiology Forecast–2030’ report delivers an in-depth understanding of the smoking cessation, historical and forecasted epidemiology as well as the smoking cessation trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Smoking Cessation Understanding Smoking cessation is the process of discontinuing tobacco smoking. When a person smokes tobacco in cigarettes, cigars or pipes, they absorb toxins that can lead to various health problems such as diabetes, cancer, chronic obstructive pulmonary disease (COPD), heart diseases, lung diseases, etc.
The main barrier to smoking cessation is nicotine addiction. Some of the most common nicotine withdrawal symptoms smokers face when they try to quit smoking include craving for smoking, mood swings, insomnia, constipation, increased appetite, anxiety, etc.
Smoking Cessation Symptoms Stopping smoking brings about a variety of symptoms associated with physical and psychological withdrawal. Most symptoms decrease sharply during the first few days of quitting, followed by a continued, but slower rate of decline in the second and third week of abstinence. For some people, coping with withdrawal symptoms is like “riding a roller coaster”—there may be sharp turns, slow climbs, and unexpected plunges. Most symptoms pass within 2–4 weeks after stopping.
Continued in the report…..
Smoking Cessation Epidemiology Perspective The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Smokers, Gender-specific Diagnosed Prevalent Cases of Smokers, Age-specific Diagnosed Prevalent Cases of Smokers and Total Diagnosed Prevalent Cases of Smoking Cessation in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Smoking Cessation Detailed Epidemiology Segmentation • The total diagnosed prevalent population of Smoking Cessation in the 7MM was 49,301,950 in 2017.
• The United States showed the highest diagnosed prevalent cases of smokers, as compared to EU5, and Japan. In 2017, the number of smokers in the US was estimated to be 35,288,932.
• In the US, there were 19,303,046 diagnosed prevalent cases of smokers among males and 15,985,886 diagnosed prevalent cases among females in 2017.
• Out of the total 35,288,932 diagnosed prevalent cases of smokers in the US, the highest cases were observed in the age group 45–64 years (14,080,284) and the least cases were observed in 18-24 years (3,140,715) in the year 2017.
• Among the European-5 countries, Germany had the highest diagnosed prevalent population of smokers with 19,305,099 cases, followed by France with 14,044,812 cases. On the other hand, the United Kingdom had the lowest diagnosed prevalent population of 7,750,777 in 2017.
• Japan had 19,411,835 diagnosed prevalent cases of smokers in 2017 and out of this approximately 5,610,020 diagnosed cases of smoking cessation were estimated.
Scope of the Report • The report covers a descriptive overview of smoking cessation, explaining symptoms of nicotine withdrawal and barriers to smoking cessation.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of smoking cessation.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Diagnosed Prevalent Cases of Smokers, Gender-specific Diagnosed Prevalent Cases of Smokers, Age-specific Diagnosed Prevalent Cases of Smokers, and Total Diagnosed Prevalent Cases of Smoking Cessation.
Report Highlights • 11-Year Forecast of Smoking Cessation
• 7MM Coverage
• Total Diagnosed Prevalent Cases of Smoking Cessation
• Gender-specific Diagnosed Prevalent Cases of Smoking Cessation
• Age-specific Diagnosed Prevalent Cases of Smoking Cessation
• Total Diagnosed Prevalent Cases of Smoking Cessation
Key Questions Answered • What are the disease risk, burdens, and unmet needs of Smoking Cessation?
• What is the historical Smoking Cessation patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Smoking Cessation at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Smoking Cessation?
• Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of Smoking Cessation during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?
Reasons to buy The Smoking Cessation report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Smoking Cessation epidemiology forecast.
• The Smoking Cessation epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Smoking Cessation epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.
Key Assessments • Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered • The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017–2030
Our reports have been used by over 10K customers, including:
32 pages •
By Euromonitor International
• Oct 2020
2020 was a challenging year for Sanofi. It faced recalls of Zantac, one of its star OTC brands, and also had to respond to changing consumer behaviour following the COVID-19 pandemic. Overall, Sanofi has seen growth across regions over the past five years, thanks to well-established brands, as well as the ones gained in the 2017 swap with...
The 2016 Germany: Nonprescription Medicines-Products Forecast report (ISIC 47) analyzes the products sales in the total retail industry for the period 2009 through 2017. Perry/Hope Partners' reports provide the most accurate Products Forecasts based on our proprietary economic models. Our forecasts project the number of enterprises,...
Summary The G8 OTC Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures...
Summary Global OTC Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures...
Consumer Price Index
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.